Health Care
Commentary
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Commentary
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Commentary
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Commentary
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Commentary
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Commentary
Medicaid isn’t a federal entitlement
Sen. Bill Cassidy (R-LA) recently ripped into progressives for opposing Medicaid reform. “Medicaid is meant to be a state-federal partnership,” Cassidy, who has an M.D., wrote on X. “States are supposed to pay for 40% of the cost. Most states are paying for less than 15%. … People should not ...
Commentary
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Commentary
Medicaid can’t survive without spending cuts
Congressional Republicans are trying to figure out what to do with Medicaid. Nearly 80 million Americans get health coverage through the entitlement. In California, one in three residents has Medi-Cal, the Golden State’s version of Medicaid. Congress will have to rein in the program at some point. Spending on the ...
Direct-To-Consumer Ozempic Sales Are A Win For Patients And Drug Makers
Google Wegovy. Or Zepbound. The search results offer a preview of a direct-to-consumer future for prescription drugs. The brand-name drugs’ homepages generally get top billing. But not far down are ads for telehealth companies promising access to the drugs or others with the same active pharmaceutical ingredient, or API, without ...
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
Congressional Republicans are under pressure to find savings to make the math in their budget reconciliation package add up. Medicaid, which accounts for just under 10% of federal spending, has become an obvious target. But instead of addressing the flawed incentives driving the program’s unsustainability, the Trump administration is pushing ...
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Congress Should Not Impose Foreign Price Controls On Innovative Drugs
Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. ...
Medicaid isn’t a federal entitlement
Sen. Bill Cassidy (R-LA) recently ripped into progressives for opposing Medicaid reform. “Medicaid is meant to be a state-federal partnership,” Cassidy, who has an M.D., wrote on X. “States are supposed to pay for 40% of the cost. Most states are paying for less than 15%. … People should not ...
Medicaid Is Not A Test Lab For Foreign Price Controls
In a desperate bid to claim fiscal discipline without touching entitlements, President Donald J. Trump is pushing congressional Republicans to adopt a “most favored nation” (MFN) drug pricing model for Medicaid. This policy would tie Medicaid reimbursements to the lowest prices paid in other developed countries—countries where government officials dictate ...
Medicaid can’t survive without spending cuts
Congressional Republicans are trying to figure out what to do with Medicaid. Nearly 80 million Americans get health coverage through the entitlement. In California, one in three residents has Medi-Cal, the Golden State’s version of Medicaid. Congress will have to rein in the program at some point. Spending on the ...
